MREO

Mereo BioPharma Group plc

3.82 USD
+0.09 (+2.41%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Mereo BioPharma Group plc stock is up 1.87% since 30 days ago. The next earnings date is Sep 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 February’s closed higher than January. In the last 8 Unusual Options Trades, there were 8 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Jan 15:23 16 Feb, 2024 2.50 CALL 200 3798
29 Jan 15:52 15 Mar, 2024 2.50 CALL 200 93
30 Jan 16:16 16 Feb, 2024 2.50 CALL 340 3736
30 Jan 16:17 17 May, 2024 2.50 CALL 149 3024
30 Jan 16:17 17 May, 2024 2.50 CALL 223 3024
30 Jan 16:18 16 Feb, 2024 2.50 CALL 340 3736
30 Jan 16:18 17 May, 2024 2.50 CALL 208 3024
16 Feb 16:11 16 Aug, 2024 2.50 CALL 200 210

About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.